Latest Commercial Sales News

LTR Pharma has wrapped up recruitment for its SPONTAN Phase II pharmacokinetic study, with interim results expected soon to bolster FDA approval efforts. Meanwhile, US commercial talks for ROXUS advance cautiously under the FDA 503(a) personalised medicine pathway.

Volt Group’s first quarter of FY26 saw ordinary revenue receipts surge 150% year-on-year to $3 million, driven by the integration of 4D Delta and strong contributions from its subsidiaries Wescone and EcoQuip.

Green360 Technologies has produced its first commercial batch of Eco-Clay under a tolling deal with Calix, advancing its low-carbon cement alternative towards market entry in Victoria by mid-2026.

Memphasys Limited has marked a milestone quarter with revenue surpassing A$100,000, driven by repeat orders and multi-year contracts, signalling its transition to a commercially focused biotech business.

Aguia Resources’ Brazilian subsidiary has achieved a key regulatory milestone with official fertiliser registration, enabling commercial sales of its PAMPAFOS phosphate product in Brazil’s large agricultural market.

Syrah Resources has opened its retail entitlement offer to raise approximately A$104 million, supported by strategic funding proposals from US and Australian government-linked entities. The capital raise aims to underpin the ramp-up of its Balama graphite mine and Vidalia anode material facility.

GCM Corporation has launched its first Very High Density (VHD) heat sink product line, marking a pivotal step from development to commercial sales in thermal management technology.

Firebrick Pharma has secured its first regulatory approval for Nasodine Nasal Spray in Indonesia, paving the way for entry into Southeast Asia’s largest market. This milestone marks a significant step in the company’s international expansion strategy.

Green360 Technologies has inked a binding toll treatment agreement with Calix Limited to commercially produce Eco-Clay, a low-carbon cement replacement, marking a key step toward scaling sustainable concrete solutions in Australia.

Rhythm Biosciences has completed the first commercial sale of its ColoSTAT® blood test for colorectal cancer, confirming the full clinical and logistical process is operational and ready for expansion.

Avecho Biotechnology has completed recruitment for the interim analysis cohort of its pivotal Phase III trial for a CBD insomnia treatment, with results expected in June 2026. This milestone could significantly de-risk the program and unlock major market opportunities.

Mesoblast Limited reported its first commercial sales of FDA-approved Ryoncil, generating $48.7 million in net product sales for the half-year ended December 31, 2025, while reducing its net loss by 16%. The company also secured a $125 million five-year credit facility, restructuring its debt to support ongoing commercialization and development.